125,508 results match your criteria Pancreatic Cancer


Gastrointest Endosc 2022 May 23. Epub 2022 May 23.

Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita Salute San Raffaele University, Milan, Italy.

Background And Aims: Pancreatic Cystic Neoplasms (PCNs) represent a difficult preoperative diagnosis despite imaging improvement. In this study, we compare preoperative and final pathological diagnosis in a large cohort of resected PCNs, evaluating diagnostic accuracy with a specific focus on the value of Endoscopic Ultrasound (EUS).

Methods: A retrospective analysis of patients undergoing resection between 2009 and 2019 for presumed PCNs was performed. Read More

View Article and Full-Text PDF

Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models.

Biomed Pharmacother 2022 May 23;151:113163. Epub 2022 May 23.

Division of Gastroenterology, Fondazione IRCCS Casa Sollievo della Sofferenza, Viale dei Cappuccini, 1, 71013 San Giovanni Rotondo, FG, Italy. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer. The characteristic excessive stromatogenesis accompanying the growth of this tumor is believed to contribute to chemoresistance which, together with drug toxicity, results in poor clinical outcome. An increasing number of studies are showing that gut microbiota and their metabolites are implicated in cancer pathogenesis, progression and response to therapies. Read More

View Article and Full-Text PDF

A pH-sensor scaffold for mapping spatiotemporal gradients in three-dimensional in vitro tumour models.

Biosens Bioelectron 2022 May 18;212:114401. Epub 2022 May 18.

Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy. Electronic address:

The detection of extracellular pH at single cell resolution is challenging and requires advanced sensibility. Sensing pH at high spatial and temporal resolution might provide crucial information in understanding the role of pH and its fluctuations in a wide range of physio-pathological cellular processes, including cancer. Here, a method to embed silica-based fluorescent pH sensors into alginate-based three-dimensional (3D) microgels tumour models, coupled with a computational method for fine data analysis, is presented. Read More

View Article and Full-Text PDF

Pancreaticoduodenectomy for pancreatic adenocarcinoma in a patient with situs inversus abdomenalis, a case report.

Int J Surg Case Rep 2022 May 18;95:107220. Epub 2022 May 18.

Radiology Department, Assiut University Hospital, Assiut University, Egypt.

Introduction And Importance: Situs Inversus (SI) is a rare congenital condition in which the abdominal and thoracic organs are located in a mirror image of the normal position in the sagittal plane. Although this condition does not affect normal health or longevity, its recognition is very important for treating many diseases, particularly those requiring surgical intervention. The relationship between situs inversus and cancer remain inconspicuous. Read More

View Article and Full-Text PDF

Patient-derived Organoids Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.

Clin Cancer Res 2022 May 26. Epub 2022 May 26.

University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

The patient-derived organoids (PDOs) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard of care chemotherapy agents in the PDOs platform has shown promising sensitivities to guide precision medicine for individual PDAC patients within a clinically relevant time frame. Read More

View Article and Full-Text PDF

Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma.

PLoS One 2022 26;17(5):e0266620. Epub 2022 May 26.

Division of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe, Hyogo, Japan.

Objectives: Small proline-rich protein 1A (SPRR1A) is recognized as a squamous differentiation marker but is also upregulated in some non-squamous cancers. However, its expression in pancreatic ductal adenocarcinoma (PDAC) has not been investigated. This study elucidated the expression of SPRR1A in PDAC and its effect on the prognosis and malignant behavior of PDAC. Read More

View Article and Full-Text PDF

Acquired chemoresistance drives spatial heterogeneity, chemoprotection and collective migration in pancreatic tumor spheroids.

PLoS One 2022 26;17(5):e0267882. Epub 2022 May 26.

Cornell University, Ithaca, New York, United States of America.

Tumors display rich cellular heterogeneity and typically consist of multiple co-existing clones with distinct genotypic and phenotypic characteristics. The acquisition of resistance to chemotherapy has been shown to contribute to the development of aggressive cancer traits, such as increased migration, invasion and stemness. It has been hypothesized that collective cellular behavior and cooperation of cancer cell populations may directly contribute to disease progression and lack of response to treatment. Read More

View Article and Full-Text PDF

Feasibility of Cholangioscopy Using Multibending Ultra-Slim Endoscope Through a Lumen-Apposing Metal Stent for Choledochoduodenostomy.

Dig Dis Sci 2022 May 26. Epub 2022 May 26.

Digestive Disease Center and Research Institute, Department of Internal Medicine, SoonChunHyang University School of Medicine, Cheonan, Korea.

Background And Aims: Endoscopic ultrasound (EUS) guided choledochoduodenostomy using a lumen-apposing metal stent (LAMS) allows access to the biliary system with a sufficiently large diameter stent. However, an appropriate endoscope for this purpose is required. We evaluated the feasibility of per-oral cholangioscopy (POC) using a multibending ultra-slim endoscope through a LAMS for EUS-guided choledochoduodenostomy. Read More

View Article and Full-Text PDF

ASO Author Reflections: Nationwide Reflection of Clinical Outcomes in Elderly Patients after Resection of Pancreatic Cancer.

Ann Surg Oncol 2022 May 26. Epub 2022 May 26.

Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.

View Article and Full-Text PDF

AZD5305 More Tolerable than 1st-Generation PARP Inhibitors.


Cancer Discov 2022 May 26:OF1. Epub 2022 May 26.

Findings from the phase I/IIa trial of AZD5305, a next-generation, highly selective PARP1 inhibitor, indicate that the drug is better tolerated in patients with ovarian, HER2-negative breast, pancreatic, and prostate cancers with BRCA1/2, PALB2, and RAD51C mutations compared with first-generation PARP inhibitors. In addition, 25% of 40 evaluable patients had a partial response. Read More

View Article and Full-Text PDF

Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.

J Surg Oncol 2022 May 26. Epub 2022 May 26.

Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.

Background: To define surgical outcomes of patients with high-grade gastro-entero-pancreatic neuroendocrine neoplasm grade G3 (GEP-NEN G3).

Methods: Patients who underwent surgical resection between 2000 and 2016 were identified. The overall survival (OS) and recurrence-free survival (RFS) of patients with gastro-entero-pancreatic neuroendocrine tumors grade G3 (GEP-NET G3) versus neuroendocrine carcinoma (NEC) were evaluated. Read More

View Article and Full-Text PDF

Comment on: Collaborative research in surgery: a rising tide lifts all boats.

Br J Surg 2022 May 25. Epub 2022 May 25.

Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

View Article and Full-Text PDF

Enhancing Photodynamic Therapy Efficacy Against Cancer Metastasis by Ultrasound-Mediated Oxygen Microbubble Destruction to Boost Tumor-Targeted Delivery of Oxygen and Renal-Clearable Photosensitizer Micelles.

ACS Appl Mater Interfaces 2022 May 26. Epub 2022 May 26.

Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China.

Hypoxic tumor microenvironment and nonspecific accumulation of photosensitizers are two key factors that limit the efficacy of photodynamic therapy (PDT). Herein, a strategy of oxygen microbubbles (MBs) boosting photosensitizer micelles is developed to enhance PDT efficacy and inhibit tumor metastasis by self-assembling renal-clearable ultrasmall poly(ethylene glycol)-modified protoporphyrin IX micelles (PPM) and perfluoropentane (PFP)-doped oxygen microbubbles (OPMBs), followed by ultrasound imaging-guided OPMB destruction to realize the tumor-targeted delivery of PPM and oxygen in tumor. Doping PFP into oxygen MBs increases the production of MBs and stability of oxygen MBs, allowing for persistent circulation in blood. Read More

View Article and Full-Text PDF

Calcitonin: current concepts and differential diagnosis.

Ther Adv Endocrinol Metab 2022 21;13:20420188221099344. Epub 2022 May 21.

5th Surgical Clinic, Department of Surgery, 'Evgenidion Hospital', National and Kapodistrian University of Athens Medical School, Athens, Greece.

Calcitonin (CT) is most effectively produced by the parafollicular cells of the thyroid gland. It acts through the calcitonin receptor (CTR), a seven-transmembrane class II G-protein-coupled receptor linked to multiple signal transduction pathways with its main secretagogues being calcium and gastrin. It is clinically used mostly in the diagnosis and follow-up of medullary thyroid carcinoma (MTC). Read More

View Article and Full-Text PDF

Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma.

ANZ J Surg 2022 May 25. Epub 2022 May 25.

Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

Background: Computed tomography (CT) is the first-line staging imaging modality for pancreatic ductal adenocarcinoma (PDAC) which determines resectability and treatment pathways.

Methods: Between January 2016 and December 2019, prospectively collated data from two Australian cancer centres was extracted from the PURPLE Pancreatic Cancer registry. Real-world staging CTs and corresponding reports were blindly reviewed by a sub-specialist radiologist and compared to initial reports. Read More

View Article and Full-Text PDF

Imaging PARP with [F]rucaparib in pancreatic cancer models.

Eur J Nucl Med Mol Imaging 2022 May 26. Epub 2022 May 26.

Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, OX3 7DQ, Oxford, UK.

Purpose: Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the same benefit from rucaparib-maintenance therapy. A predictive biomarker to help with patient selection for rucaparib treatment and predict clinical benefit is therefore warranted. Read More

View Article and Full-Text PDF

FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.

Cell Death Dis 2022 May 25;13(5):497. Epub 2022 May 25.

Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China.

Pancreatic cancer (PC) is one of the deadliest malignant tumors, and its resistance to gemcitabine chemotherapy is the primary reason for poor prognosis in patients. Ubiquitin-like protein FAT10 has recently been reported to promote tumor chemotherapy resistance. In this study, the expression of FAT10 in PC was significantly higher than that in adjacent noncancerous tissues. Read More

View Article and Full-Text PDF

Robust Descriptor of Pancreatic Tissue for Automatic Detection of Pancreatic Cancer in Endoscopic Ultrasonography.

Ultrasound Med Biol 2022 May 22. Epub 2022 May 22.

Computer Imaging and Medical Applications Laboratory, Universidad Nacional de Colombia, Bogotá, Colombia. Electronic address:

Pancreatic cancer (PC) has a reported mortality of 98% and a 5-y survival rate of 6.7%. Experienced gastroenterologists detect 80% of those with early-stage PC by endoscopic ultrasonography (EUS). Read More

View Article and Full-Text PDF

Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.

Pancreatology 2022 May 14. Epub 2022 May 14.

Department of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address:

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in an advanced stage, with minimal likelihood of long-term survival. Only a small subset of patients are diagnosed with early (T1) disease. Early detection is challenging due to the late onset of symptoms and limited visibility of sub-centimeter cancers on imaging. Read More

View Article and Full-Text PDF

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.

JCO Precis Oncol 2022 May;6:e2200085

Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.

Purpose: Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate. In these cancers, / alterations and genomic scar signatures are useful indicators for assessing HRD. However, alterations in other homologous recombination repair (HRR)-related genes and their clinical significance in other cancer types have not been adequately and systematically investigated. Read More

View Article and Full-Text PDF

[There is a role for surgical resection in patients with oligometastatic pancreatic cancer].

Rev Gastroenterol Peru 2021 Oct-Dec;41(4):233-238

Clínica Delgado. Lima, Perú.

Objective: The objective of this work is to retrospectively analyze the resection in patients with oligometastatic stage IV pancreatic adenocarcinoma, after first-line chemotherapy for metastatic pancreatic cancer, evaluating the survival of these cases.

Materials And Methods: Between January 2005 and December 2019, 5 patients diagnosed with oligometastatic pancreatic cancer undergoing first-line chemotherapy were retrospectively evaluated, after which resective surgery was performed.

Results: The resective surgery performed in these patients were: three distal pancreatectomies with splenectomy, one duodenopancreatectomy and one total pancreatectomy. Read More

View Article and Full-Text PDF

Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.

JAMA Surg 2022 May 25:e221362. Epub 2022 May 25.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Importance: The use of neoadjuvant therapy (NAT) in resectable pancreatic ductal adenocarcinoma (PDAC) remains controversial. A favorable pathologic response (complete or marked tumor regression) to NAT is associated with better outcomes in patients with resected PDAC. The role of NAT for early systemic control compared with immediate surgical resection for PDAC is under investigation. Read More

View Article and Full-Text PDF

Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes.

Am J Med Genet A 2022 May 25. Epub 2022 May 25.

Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

We aimed to further characterize pancreatic involvement in tuberous sclerosis complex (TSC), with a focus on management of TSC-associated nonfunctional pancreatic neuroendocrine tumors (PNETs). This was a retrospective chart review of a large cohort of TSC patients. A total of 637 patients with a confirmed diagnosis of TSC were seen at the Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital. Read More

View Article and Full-Text PDF

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study.

Anal Methods 2022 May 25. Epub 2022 May 25.

ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW 2109, Australia.

Circulating pancreatic ductal adenocarcinoma (PDAC) derived small extracellular vesicles (sEVs) are nano-sized membranous vesicles secreted from PDAC cells and released into surrounding body fluids, such as blood. The use of plasma-derived sEVs for cancer diagnosis is particularly appealing in biomedical research because the sEVs reflect some key features ( genetic and phenotypic status) related to the organs from which they originate. For example, the surface membrane proteins and their expression level on sEVs were reported to be related to the presence and progression of PDAC. Read More

View Article and Full-Text PDF

Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.

Drug Deliv 2022 Dec;29(1):1595-1607

College of Materials Science and Engineering, Research Institute for Biomaterials, Tech Institute for Advanced Materials, Nanjing Tech University, Nanjing, PR China.

At present, the 10-year survival rate of patients with pancreatic cancer is still less than 4%, mainly due to the high cancer recurrence rate caused by incomplete surgery and lack of effective postoperative adjuvant treatment. Systemic chemotherapy remains the only choice for patients after surgery; however, it is accompanied by off-target effects and server systemic toxicity. Herein, we proposed a biodegradable microdevice for local sustained drug delivery and postoperative pancreatic cancer treatment as an alternative and safe option. Read More

View Article and Full-Text PDF
December 2022

Utility of Diffusion-Weighted MRI for Detection of Locally Recurrent Pancreatic Cancer After Surgical Resection.

AJR Am J Roentgenol 2022 May 25. Epub 2022 May 25.

Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.

Overlapping imaging findings between local tumor recurrence and post-surgical fibrosis represent a major clinical challenge after pancreatic ductal adenocarcinoma (PDAC) resection. To compare the diagnostic performance of MRI with and without DWI for differentiating locally recurrent tumor and post-surgical fibrosis after PDAC resection. This retrospective study included 66 patients (35 men, 31 women; mean age, 60. Read More

View Article and Full-Text PDF

Carbohydrates based stimulus responsive nanocarriers for cancer-targeted chemotherapy: A review of current practices.

Expert Opin Drug Deliv 2022 May 25. Epub 2022 May 25.

General Surgery, Cancer Center, Department of hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital of Hangzhou Medical College), Hangzhou, Zhejiang, China.

Introduction: Many nanocarriers have been developed to react physicochemically to exterior stimuli like ultrasonic, light, heat, and magnetic fields, along with various internal stimuli including pH, hypoxia, enzyme, and redox potential. Nanocarriers are capable to respond various stimuli within the cancer cells to enable on-demand drug delivery, activation of bioactive compounds, controlled drug release, and targeting ligands, as well as size, charge, and conformation conversion, enabling sensing and signaling, overcoming multidrug resistance, accurate diagnosis, and precision therapy.

Areas Covered: Carbohydrates are ubiquitous biomolecules with a high proclivity for supramolecular network formation. Read More

View Article and Full-Text PDF

Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression.

Acta Oncol 2022 May 25:1-9. Epub 2022 May 25.

Division of Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.

Background: The effectiveness of abdominal compression for motion management in hepatobiliary-pancreatic (HPB) radiotherapy has not been systematically evaluated.

Methods & Materials: A systematic review was carried out using PubMed/Medline, Cochrane Library, Web of Science, and CINAHL databases up to 1 July 2021. No date restrictions were applied. Read More

View Article and Full-Text PDF

Low Carbohydrate Antigen 19-9 (CA 19-9) Levels in a Patient Highly Suspected of Having Caput Pancreas Tumor.

Cureus 2022 Apr 21;14(4):e24357. Epub 2022 Apr 21.

Internal Medicine, Wangaya Regional Hospital, Bali, IDN.

Pancreatic cancer is the seventh leading cause of cancer-related mortality worldwide and the eleventh most common cause of cancer-related death in Indonesia. In pancreatic cancer, rapid and early diagnosis is crucial. Carbohydrate antigen 19-9 (CA 19-9), the most sensitive and specific tumor marker for pancreatic cancer, may help in diagnosing and determining prognosis; however, some populations do not express CA 19-9. Read More

View Article and Full-Text PDF